Mouse Monoclonal Cytokeratin 19 antibody. Carrier free. Suitable for IHC-P and reacts with Human samples. Immunogen corresponding to Cell preparation containing Keratin, type I cytoskeletal 19 protein.
pH: 7.2 - 7.4
Constituents: 100% PBS
IHC-P | |
---|---|
Human | Tested |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 0.5-1 µg/mL | Notes 30 minutes at room temperature. Perform heat-mediated antigen retrieval with citrate buffer pH 6 before commencing with IHC staining protocol. |
Select an associated product type
Involved in the organization of myofibers. Together with KRT8, helps to link the contractile apparatus to dystrophin at the costameres of striated muscle.
Cytokeratin-19, Keratin-19, CK-19, K19, KRT19
Mouse Monoclonal Cytokeratin 19 antibody. Carrier free. Suitable for IHC-P and reacts with Human samples. Immunogen corresponding to Cell preparation containing Keratin, type I cytoskeletal 19 protein.
pH: 7.2 - 7.4
Constituents: 100% PBS
ab212569 reacts with the rod domain of Human Cytokeratin 19.
Purified from bioreactor concentrate by Protein A/G.
Cytokeratin 19 (CK19) also known as cytokeratine 19 keratin 19 (KRT19) or CK19 is a type of intermediate filament found in epithelial cells. It serves as an essential component of the cytoskeleton. CK19 weighs approximately 40 kDa and is broadly expressed in simple epithelial tissues including liver intestine and various glandular epithelial cells. As a cytokeratin marker it often appears in combination with others like cytokeratin 17 in certain tissue types helping to maintain the structural integrity of cells.
CK19 plays a role in maintaining the cytoskeletal framework that provides mechanical support and helps control cell size and shape. It is not part of a large protein complex but works closely with other cytokeratins to ensure the stability and resilience of epithelial tissues. The A53-B/A22.26 positive staining is often used to confirm its presence in clinical histopathology.
CK19 connects to cellular processes especially involving the keratinization and epithelial cell differentiation pathways. It interacts with other cytokeratins including BA16 and KR17 to facilitate these processes. This interaction aids in modulating the dynamics of cytoskeletal rearrangement during cell movement division and differentiation.
CK19 overexpression is linked with certain cancers notably hepatocellular carcinoma and breast cancer. It can serve as a prognostic marker in these diseases often in conjunction with other markers like CK17. The involvement of CK19 in the epithelial-mesenchymal transition (EMT) process connects it to the progression and aggressiveness of tumors facilitated by interactions with proteins involved in EMT pathways.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Immunohistochemical analysis of formalin-fixed, paraffin-embedded Human bladder carcinoma tissue labeling Cytokeratin 19 with ab212569 at 1 μg/mL.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com